Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475800 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 833
- Enrollment target
NCT00475800 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 833 participants.
The verdict
NCT00475800, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 833 participants
- Enrollment target
Study Summary
This 39-week, open label study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2360 study.
Interventions
- DRUG Lumiracoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 833 participants |
| Start Date | 2004-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00475800
The ClinicalTrials.gov registry entry for NCT00475800 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 833 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lumiracoxib is the first listed.
NCT00475800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00475800 about?
NCT00475800 is a clinical study titled "Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)". This 39-week, open label study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2360 study.
What is the current status of trial NCT00475800?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 833 participants. The study started on 2004-01.
What interventions are being tested in trial NCT00475800?
The interventions under investigation include: Lumiracoxib (DRUG).
Who is sponsoring clinical trial NCT00475800?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.